Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Operating Leases (2023 - 2026)

MBX Biosciences has reported Operating Leases over the past 4 years, most recently at $377000.0 for Q1 2026.

  • Quarterly results put Operating Leases at $377000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $377000.0 (changed N/A YoY), and the annual figure for FY2025 was $424000.0, changed.
  • Operating Leases reached $377000.0 in Q1 2026 per MBX's latest filing, down from $424000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $512000.0 in Q2 2025 and bottomed at $44000.0 in Q3 2024.
  • Median Operating Leases over the past 4 years was $400500.0 (2025), compared with a mean of $332833.3.
  • Peak annual rise in Operating Leases hit 965.91% in 2025, while the deepest fall reached 965.91% in 2025.
  • Over 4 years, Operating Leases stood at $171000.0 in 2023, then tumbled by 74.27% to $44000.0 in 2024, then skyrocketed by 863.64% to $424000.0 in 2025, then dropped by 11.08% to $377000.0 in 2026.
  • Business Quant data shows Operating Leases for MBX at $377000.0 in Q1 2026, $424000.0 in Q4 2025, and $469000.0 in Q3 2025.